Over the last decade, targeted alpha therapy has demonstrated its high effectiveness in
treating various oncological diseases. Lead-212, with a convenient half-life of 10.64 h, and …

Existing anticancer therapeutic modalities in clinical settings lack efficacy and fail to
completely cure cancers. Clearly understandable and mechanistic approaches are …

The introduction of proteasome inhibitors (PI) and immunomodulatory drugs (IMiD) has
markedly increased the survival of multiple myeloma (MM) patients. Also, the unconjugated …

Background Antibody-based therapies targeting CD38 are currently used as single agents
as well as in combination regimens for multiple myeloma, a malignant plasma cell disorder …

Abstract Introduction 203 Pb (t 1/2= 51.9 h, 279 keV (81%)) is a diagnostic SPECT imaging
radionuclide ideally suited for theranostic applications in combination with 212 Pb for …

Receptor-targeted image-guided Radionuclide Therapy (TRT) is increasingly recognized as
a promising approach to cancer treatment. In particular, the potential for clinical translation of …

Abstract Background Despite therapeutic advances, Non-Hodgkin lymphoma (NHL)
relapses can occur. The development of radioimmunotherapy (RIT) with α-emitters is an …

Targeted therapies for multiple myeloma (MM) include the anti-CD38 antibody
daratumumab, which, in addition to its inherent cytotoxicity, can be radiolabeled with tracers …

Radioimmunotherapy (RIT) is a cancer treatment that combines radiation therapy with tumor-
directed monoclonal antibodies (Abs). Although RIT had been introduced for the treatment of …

Osteosarcoma patients with overt metastases at primary diagnosis have a 5-year survival
rate of less than 20%. TP-3 is a murine IgG2b monoclonal antibody with high affinity for an …